Mesenchymal stem cells (MSCs) have long been recognized for their potential in cancer therapy. However, the effectiveness of MSCs in cancer treatment has been hampered by their limited tumor-homing ability and the heterogeneity of tissue-derived MSCs. To address these challenges, researchers have focused on induced pluripotent stem cell (iPSC)-derived MSCs, which offer improved homogeneity and expansion potential.
A recently published study has identified collagen type X α 1 chain (CoL10A1) as a promising target for treating brain metastasis in breast cancer patients. The research, conducted by a team at First Affiliated Hospital of Xinxiang Medical University and collaborators, sheds light on the regulatory role of CoL10A1 in the progression of breast cancer brain metastasis (BMBC).
Researchers from Guilin Medical University and collaborators investigated the potential role of ubiquitin-specific protease 4 (USP4) in the occurrence and development of lung adenocarcinoma.
Abtherx Inc. has signed a technology license agreement with Rondo Therapeutics with the aim of accelerating Rondo’s pipeline of bispecific antibodies. Rondo aims to advance the field of immuno-oncology, with a focus on treating solid tumors that fail to respond to current therapies.
BRD4, a member of the BET protein family, plays a critical role in cancer progression by regulating oncogenes, particularly MYC, which drives tumor growth but is difficult to target directly. Researchers from Macau University of Science and Technology reported on the antiproliferative activity of bi-magnolignan, a novel BRD4-targeting compound isolated from the leaves of Magnolia officinalis.
Grove Biopharma Inc., a spinout from Northwestern University targeting intracellular protein-protein interactions with a novel synthetic biology-based approach, has closed a $30 million series A financing. Proceeds will be used to further advance Grove Biopharma’s Bionic Biologics platform and drive its lead oncology programs toward the clinic.
Acquired resistance to doxorubicin significantly reduces its therapeutic efficacy, limiting its clinical use in breast cancer treatment. Pan-AKR1C inhibitors have demonstrated potential in restoring drug sensitivity in resistant cancer cells.
RSS
